{"disease":{"id":"severe-pruritus","name":"Severe Pruritus","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nalfurafine","indication_name":"Severe Pruritus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remitch","generic_name":"NALFURAFINE","company_name":"","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"nalfurafine","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe anogenital pruritus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe anogenital pruritus in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05135390","title":"A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":545,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05075408","title":"To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT07098351","title":"Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis","phase":"NA","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}